Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Formula recall strategy

This article was originally published in The Tan Sheet

Executive Summary

FDA received no comments on its infant formula recall strategy, the agency says in a June 24 Federal Register notice. The proposed information collection was submitted to the Office of Management and Budget for review and clearance, though comments on the collection may be submitted to OMB through July 24. In a March 26 Federal Register notice, FDA invited comment on enhancing the quality, utility and clarity of collected information (1"The Tan Sheet" March 31, 2008, In Brief)...

Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts